Association Between Neutrophil-to-Lymphocyte Ratio and Benign Prostatic Hyperplasia: Results from the TCLSIH Cohort Study

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. doi:10.1016/j.ejca.2018.07.005
   PubMed Web of Science ®Google Scholar
• Ilic D, Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas. 2012;72(4):269–276. doi:10.1016/j.maturitas.2012.04.014
   PubMed Web of Science ®Google Scholar
• Ozer K, Horsanali MO, Gorgel SN, Horsanali BO, Ozbek E. Association between benign prostatic hyperplasia and neutrophil-lymphocyte ratio, an indicator of inflammation and metabolic syndrome. Urol Int. 2017;98(4):466–471. doi:10.1159/000448289
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–1803. doi:10.1016/j.juro.2011.01.074
   PubMed Web of Science ®Google Scholar
• Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13(3):147–150.
   PubMedGoogle Scholar
• Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol. 2014;66(4):619–622. doi:10.1016/j.eururo.2014.06.026
   PubMed Web of Science ®Google Scholar
• Ficarra V, Sekulovic S, Zattoni F, Zazzera M, Novara G. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12(5):110–115. doi:10.1016/j.eursup.2013.08.002
   Web of Science ®Google Scholar
• Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012;5(1):2. doi:10.1186/1755-7682-5-2
   PubMedGoogle Scholar
• Lee KS, Ha JS, Koo KC. Significance of neutrophil-to-lymphocyte ratio as a novel indicator of spontaneous ureter stone passage. Yonsei Med J. 2017;58(5):988–993. doi:10.3349/ymj.2017.58.5.988
   PubMed Web of Science ®Google Scholar
• Tanik S, Albayrak S, Zengin K, et al. Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev. 2014;15(15):6375–6379.
   PubMedGoogle Scholar
• Jang WS, Cho KS, Kim MS, et al. The prognostic significance of postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for localized prostate cancer. Oncotarget. 2017;8(7):11778–11787. doi:10.18632/oncotarget.14349
   PubMedGoogle Scholar
• Chung MS, Yang YJ, Lee SH, Yoon BI. Association between the neutrophil-to-lymphocyte ratio and intravesical prostatic protrusion in men with benign prostatic hyperplasia. Low Urin Tract Symptoms. 2020;12(1):62–67. doi:10.1111/luts.12287
   PubMed Web of Science ®Google Scholar
• Yu B, He H, Zhang Q, et al. Soft drink consumption is associated with depressive symptoms among adults in China. J Affect Disord. 2015;172:422–427. doi:10.1016/j.jad.2014.10.026
   PubMed Web of Science ®Google Scholar
• Song K, Du H, Zhang Q, et al. Serum immunoglobulin M concentration is positively related to metabolic syndrome in an adult population: Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) Cohort Study. PLoS One. 2014;9(2):e88701. doi:10.1371/journal.pone.0088701
   PubMed Web of Science ®Google Scholar
• Blanc M, Sacrini A, Avogadro A, et al. Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia. Radiol Med. 1998;95(3):182–187.
   PubMedGoogle Scholar
• Huh JS, Kim YJ, Kim SD. Prevalence of Benign Prostatic Hyperplasia on Jeju Island: analysis from a Cross-sectional Community-based Survey. World J Mens Health. 2012;30(2):131–137. doi:10.5534/wjmh.2012.30.2.131
   PubMedGoogle Scholar
• Zhao SC, Xia M, Tang JC, Yan Y. Associations between metabolic syndrome and clinical benign prostatic hyperplasia in a northern urban Han Chinese population: a prospective cohort study. Sci Rep. 2016;6:33933. doi:10.1038/srep33933
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497. doi:10.1001/jama.285.19.2486
   PubMed Web of Science ®Google Scholar
• Kobalava ZD, Kotovskaya YV, Babaeva LA, Moiseev VS. Validation of TM-2655 oscillometric device for blood pressure measurement. Blood Press Monit. 2006;11(2):87–90. doi:10.1097/01.mbp.0000200484.49540.12
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187. doi:10.1097/HJH.0b013e3281fc975a
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572. doi:10.1001/jama.289.19.2560
   PubMed Web of Science ®Google Scholar
• Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–1395. doi:10.1249/01.MSS.0000078924.61453.FB
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang G, Pan X. China Food Composition. Beijing: Peking University Medical Press; 2002.
   Google Scholar
• Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218–230. doi:10.1016/j.critrevonc.2013.03.010
   PubMed Web of Science ®Google Scholar
• Kang JY, Choi JD, Cho JM, Yoo TK, Park YW, Lee JH. Association of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio with benign prostatic hyperplasia: a propensity score-matched analysis. Urol Int. 2021;105(9–10):811–816. doi:10.1159/000512894
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101(Suppl 3):17–21. doi:10.1111/j.1464-410X.2008.07497.x
   PubMedGoogle Scholar
• De Nunzio C, Salonia A, Gacci M, Ficarra V. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol. 2020;38(11):2771–2779. doi:10.1007/s00345-020-03106-1
   PubMed Web of Science ®Google Scholar
• Di Silverio F, Gentile V, De Matteis A. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43(2):164–175. doi:10.1016/S0302-2838(02)00548-1
   PubMed Web of Science ®Google Scholar
• Zhang Q, Pang S, Zhang Y, Jiang K, Guo X. Association between inflammation and lower urinary tract symptoms of benign prostatic hyperplasia. Urol J. 2020;17(5):505–511. doi:10.22037/uj.v0i0.5462
   PubMed Web of Science ®Google Scholar
• Melissa M, Norström ER, Sundberg B, et al. Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget. 2016;7(17):23581–23593. doi:10.18632/oncotarget.8051
   PubMedGoogle Scholar
• Nagakura Y, Hayashi M, Kajioka S. Lifestyle habits to prevent the development of benign prostatic hyperplasia: analysis of Japanese nationwide datasets. Prostate Int. 2022;10(4):200–206. doi:10.1016/j.prnil.2022.06.004
   PubMed Web of Science ®Google Scholar
• Chung GE, Yim JY, Kim D, et al. Nonalcoholic fatty liver disease is associated with benign prostate hyperplasia. J Korean Med Sci. 2020;35(22):e164. doi:10.3346/jkms.2020.35.e164
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Sarma AV, Jacobson DJ, et al. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol. 2009;169(11):1281–1290. doi:10.1093/aje/kwp085
   PubMed Web of Science ®Google Scholar